PMC8593254_01
Graphs showing the platelet count, ADAMTS13 activity, and the anti-ADAMTS13 antibody trend correlated with the administered therapies in our two cases.
fped-09-743206-g0001.jpg
PMC8593254_02_fped-09-743206-g0001.jpg
F1
Platelet count remained normal even when PEX and caplacizumab were discontinued (Figure 1).
PMC8593254_02
Graphs showing the platelet count, ADAMTS13 activity, and the anti-ADAMTS13 antibody trend correlated with the administered therapies in our two cases.
fped-09-743206-g0001.jpg
PMC8593254_02_fped-09-743206-g0001.jpg
F1
Platelet count remained normal even when PEX and caplacizumab were discontinued (Figure 1).